Clinical Trial Protocol Review Checklist: What Every Regulatory Reviewer Must Check

A clinical trial protocol is the foundational document governing how a study will be conducted. It defines the study question, the study design, who can participate, what will be measured, how safety will be monitored, and how the data will be analyzed. Deficiencies in the protocol create problems that compound throughout the study — recruiting patients who should have been excluded, measuring the wrong endpoints, or applying statistical analyses that do not answer the study question.

Protocol review happens at multiple levels: sponsor internal review before submission; IRB/IEC review for ethical appropriateness; FDA review through the IND process; and institutional review at each participating site. Each review serves a different purpose, but all share the goal of ensuring the study is scientifically sound, ethically conducted, and capable of generating data that will support regulatory and scientific decision-making.

This checklist covers the critical elements that reviewers at each level should verify before approving a protocol for implementation.

Section 1: Administrative and Identification Information

Before reviewing the scientific content, verify the administrative completeness:

• [ ] Protocol title accurately reflects the study design, indication, and phase
• [ ] Protocol version number and date are clearly stated on every page (including headers/footers)
• [ ] IND number is cited (for studies conducted under an IND)
• [ ] Sponsor name and contact information are current
• [ ] Investigator of Record / Principal Investigator identified with credentials and institutional affiliation
• [ ] ClinicalTrials.gov registration number (required for studies of regulated products)
• [ ] List of protocol amendments and dates (for amended protocols — verify this version supersedes the prior version)
• [ ] Signature block for sponsor approval and investigator agreement
• [ ] Applicable regulatory references cited (ICH E6 GCP, 21 CFR Part 50/56/312 for US studies)

---

Section 2: Background and Rationale

The background section justifies conducting the study. A well-written rationale answers: why this drug? why this population? why this dose? why now?

• [ ] Disease/condition background is accurate and current (updated within the past 12-18 months for fast-moving areas)
• [ ] Current standard of care is accurately described — are there recently approved treatments that should be discussed?
• [ ] Unmet medical need is clearly articulated — what gap in current treatment does this study address?
• [ ] Preclinical pharmacology supporting the proposed mechanism of action is summarized with study references
• [ ] Nonclinical toxicology summary establishes the safety basis for the proposed dose range in humans
• [ ] Prior clinical experience with the drug is summarized accurately:
  • [ ] Phase 1 PK/PD data and dose selection rationale
  • [ ] Preliminary efficacy signals from Phase 2 (if Phase 3 protocol)
  • [ ] Known safety signals and their management
• [ ] Rationale for dose and dosing regimen is scientifically justified
• [ ] Rationale for the proposed patient population is supported by evidence
• [ ] Reference to the current Investigator's Brochure (version and date)

Common deficiencies:

• Background that does not acknowledge recent competitive approvals in the indication
• Dose rationale that references unpublished internal data not available to reviewers
• Missing discussion of safety signals observed in prior studies with the drug or drug class

---

Section 3: Study Objectives and Endpoints

The objectives and endpoints section defines what the study is designed to answer. This is the most critical section for regulatory reviewers — unclear or inappropriate endpoints invalidate the study as a basis for regulatory decision-making.

Primary Objective and Endpoint

• [ ] Primary objective is a clear, unambiguous statement of the primary scientific question
• [ ] Primary endpoint is:
  • [ ] Clinically meaningful (or validated as a surrogate for clinical benefit)
  • [ ] Measurable using an objective, standardized assessment method
  • [ ] Measured at a clearly specified time point
  • [ ] Consistent with the primary objective
  • [ ] Acceptable to the regulatory agency for the intended claim (has this endpoint been discussed with FDA/EMA?)
• [ ] For patient-reported outcomes (PROs): is the PRO instrument validated for this indication and patient population?
• [ ] For surrogate endpoints: has FDA accepted this surrogate as reasonably likely to predict clinical benefit?

Secondary Objectives and Endpoints

• [ ] Secondary endpoints are clearly listed with corresponding assessments and time points
• [ ] Hierarchical testing plan specified (to control Type I error across multiple endpoints)
• [ ] Any key secondary endpoints designated as confirmatory vs. exploratory are clearly distinguished
• [ ] Exploratory endpoints are clearly labeled as exploratory

Biomarker Endpoints

• [ ] Biomarker assay is validated (if biomarker is a secondary or exploratory endpoint)
• [ ] Biomarker endpoint analysis plan (validated assay, reference laboratory, analysis timing) is specified
• [ ] Pharmacokinetic objectives and sampling schedule are defined

Common deficiencies:

• Primary endpoint not pre-specified with adequate precision — leaving ambiguity about exactly what will be measured and when
• Multiple primary endpoints without adequate multiplicity adjustment
• Surrogate endpoints not previously discussed with or accepted by FDA for the indication
• PRO endpoints without validated instruments or clear responder definitions

---

Section 4: Study Design

• [ ] Study design type is clearly stated: randomized controlled trial, open-label, single-arm, cross-over, adaptive
• [ ] Blinding: is the study double-blind, single-blind, or open-label? Are all parties appropriately blinded (sponsor, investigator, patient, assessor)?
• [ ] Randomization method specified (centralized IVRS/IWRS, block randomization, stratification factors)
• [ ] Stratification factors are clinically justified and operationally feasible
• [ ] Control arm is appropriate: placebo, active comparator, standard of care?
• [ ] Comparator selection is justified — is the comparator consistent with current standard of care?
• [ ] Study duration is adequate to observe the primary endpoint
• [ ] Study phases clearly defined: screening, baseline, treatment period(s), follow-up
• [ ] For adaptive designs:
  • [ ] Adaptation rules are pre-specified
  • [ ] Statistical type I error control is addressed
  • [ ] Blinding of adaptation decisions is described
  • [ ] Regulatory agency has been consulted about the adaptive design

---

Section 5: Study Population — Eligibility Criteria

Eligibility criteria define who can participate. Overly restrictive criteria impair enrollment; overly permissive criteria enroll patients at higher risk or those unlikely to respond to treatment.

Inclusion Criteria

• [ ] Each inclusion criterion is:
  • [ ] Medically necessary for the study (not unnecessarily restrictive)
  • [ ] Operationally feasible to assess at screening
  • [ ] Measurable using standardized, reproducible methods
• [ ] Diagnosis criteria reference a recognized standard (DSM-5 for psychiatric diagnoses, validated staging criteria for oncology, etc.)
• [ ] Age range is appropriate for the indication and consistent with the target population
• [ ] Severity requirements (ECOG status, disease stage, symptom scale score) are clinically appropriate
• [ ] Required laboratory values are within ranges achievable in the target population
• [ ] Reproductive status requirements comply with local law and ICH guidance

Exclusion Criteria

• [ ] Each exclusion criterion has a clear clinical justification (safety concern, confounding effect, or scientific rationale)
• [ ] Washout periods for prohibited medications are clinically justified
• [ ] Pregnancy and lactation exclusions are present and appropriate
• [ ] Prior therapy exclusions are appropriate given the treatment setting
• [ ] Exclusions for concurrent diseases or conditions are limited to those that create genuine safety risk or confounding
• [ ] No discriminatory exclusions that are not medically justified

Common deficiencies:

• Exclusion criteria that would exclude most patients seen in clinical practice (threatening generalizability)
• Prior therapy washout periods that are not clinically justified
• Laboratory thresholds set at levels that would exclude patients with the target condition

---

Section 6: Study Treatments

• [ ] Investigational drug name, formulation, dose, route, and schedule clearly specified
• [ ] Dose modifications and dose reduction rules are pre-specified for all expected toxicities
• [ ] Dose modification criteria are clinically appropriate and specific (not vague)
• [ ] Prohibited concomitant medications list is complete and clinically justified
• [ ] Drug supply, packaging, and labeling requirements are referenced
• [ ] Blinding/unblinding procedures are specified (for blinded studies)
• [ ] Treatment compliance assessment methods are defined
• [ ] Comparator/placebo is clearly specified
• [ ] For combination therapy protocols: all agents, doses, and schedules are specified

---

Section 7: Safety Monitoring and Adverse Event Management

This section is the highest-priority area for safety reviewers and IRBs.

Adverse Event Definitions and Reporting

• [ ] Adverse event (AE), serious adverse event (SAE), and adverse event of special interest (AESI) definitions are consistent with ICH E6 and applicable regulations
• [ ] SAE reporting timelines are specified (expedited reporting within 15 calendar days to FDA, 24 hours to IRBs for unexpected serious related AEs)
• [ ] AE grading scale is specified (typically CTCAE for oncology; NCI CTCAE version should be specified)
• [ ] AESI list is appropriate given the known safety profile of the drug class
• [ ] Causality assessment responsibilities are clear

Data Safety Monitoring Board (DSMB) / Independent Data Monitoring Committee (IDMC)

• [ ] DSMB/IDMC is required? (Required for large Phase 3 trials, any trial with high mortality risk, any blinded randomized trial)
• [ ] DSMB charter referenced or summarized
• [ ] DSMB review frequency and triggers for unscheduled reviews specified
• [ ] Stopping rules are pre-specified, measurable, and statistically appropriate

Dose-Limiting Toxicities and Maximum Tolerated Dose (Phase 1)

• [ ] DLT definition is specific, measurable, and clinically appropriate
• [ ] DLT observation period is sufficient
• [ ] Dose escalation rules are clearly defined (number of DLTs triggering escalation hold or de-escalation)
• [ ] Maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D) determination criteria are pre-specified

---

Section 8: Statistical Considerations

The statistical section defines how the study will be analyzed and is the basis for determining whether the study can generate evidence sufficient for its intended purpose.

• [ ] Primary analysis population defined: ITT (intent-to-treat), mITT, per-protocol, safety population
• [ ] Sample size calculation is specified with:
  • [ ] Assumed effect size
  • [ ] Alpha (Type I error) and power (1 − Type II error)
  • [ ] Assumption basis (prior data or published literature)
  • [ ] Dropout/loss-to-follow-up assumption and its justification
• [ ] Multiplicity adjustment is pre-specified for all confirmatory endpoints
• [ ] Missing data handling strategy is pre-specified
• [ ] Primary efficacy analysis method is fully specified
• [ ] Secondary and exploratory analyses are clearly described as such
• [ ] Interim analyses: if pre-specified, stopping rules and alpha spending function are defined
• [ ] Subgroup analyses: if pre-specified, which subgroups and the rationale for each

Common deficiencies:

• Sample size not powered for the primary endpoint under realistic assumptions
• Missing data handling described vaguely or inconsistent with ICH E9(R1)
• Subgroup analyses added without pre-specification or multiplicity adjustment

---

Section 9: Regulatory and Ethical Compliance

• [ ] Reference to applicable regulations (21 CFR Part 50, 56, 312; ICH E6 R2)
• [ ] IRB/IEC approval requirements specified
• [ ] Informed consent requirements: all required elements per 21 CFR Part 50 are present in the template consent form
• [ ] Privacy protections specified (HIPAA authorization for US studies, GDPR for EU studies)
• [ ] Special protections for vulnerable populations (children, pregnant women, prisoners) addressed if applicable
• [ ] Conflict of interest disclosure requirements specified
• [ ] Data sharing and publication policy referenced

---

Using AI to Review Clinical Trial Protocols

Clinical trial protocols often run 80-200 pages with dense technical content. The Regulatory Submission Analyzer can extract key protocol elements with page citations — primary endpoint definition, eligibility criteria, statistical assumptions, DSMB composition — enabling faster identification of the sections that require the most focused human review.

For regulatory affairs teams managing multiple active trials, uploading multiple protocols to a collection enables cross-protocol questions: "How do the stopping rules compare across our three active oncology protocols?" or "Which of our protocols include biomarker sub-studies?"

Key Regulatory Terms

• IND Application: Clinical protocols are submitted as IND amendments — each protocol change requires IND notification
• Clinical Data Package: The complete set of clinical study results that a protocol is designed to generate
• cGMP: Manufacturing quality standards governing the investigational drug supply for clinical trials
• Regulatory Intelligence: Monitoring FDA guidance on endpoint acceptability, study design, and safety monitoring requirements

---

Upload any clinical trial protocol to the Regulatory Submission Analyzer to extract key design elements, identify potential deficiencies, and get cited answers to specific protocol questions — with page references to the exact location in the document.